Protara Completes Enrollment in Phase 2b Portion of IV Choline Chloride Trial
Bitget2026/10/15 12:01- Protara Therapeutics completed enrollment of 24 patients in the Phase 2b dose-confirmation portion of its registrational THRIVE-3 trial of IV Choline Chloride.
- The treatment targets choline deficiency in patients with intestinal failure who depend on parenteral support.
- Interim Phase 2b results are expected in the fourth quarter of 2026; the study will guide dose selection.
- The randomized, placebo-controlled Phase 3 portion will enroll approximately 100 patients to evaluate improvement in plasma choline levels and safety.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
